A Phase 2 clinical trial involving cagrilintide has been marked as completed, according to a status update dated September 24, 2026. The study, registered as NCT06131372, is titled "A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo."
The trial compared CagriSema, semaglutide, cagrilintide, and placebo in participants with chronic kidney disease and type 2 diabetes who are living with overweight or obesity. It was designed to examine whether kidney damage in this population could be reduced.
The registry entry lists the trial phase as Phase 2 and the current status as completed. No results, outcome data, or efficacy conclusions are included in this update. Cagrilintide remains an unapproved compound classified for research use.
This brief reflects only the status change recorded in the trial registry as of the listed date. Further detail on trial design, endpoints, or eventual findings would require separate disclosure through the registry or a peer reviewed publication.
For more background on this compound, see the linked compound overview.